Utah Medical Products 2Q FY26 net income falls 11.9% to USD 2.69 million; net sales drop 14.3% to USD 8.53 million
Reuters2026/08/12 18:01- Utah Medical Products posted 2Q 2026 net income of USD 2.69 million, down 11.9% year over year; diluted EPS fell 10.1% to USD 0.84.
- Net sales dropped 14.3% to USD 8.53 million; management cited no sales to two previously largest customers.
- Operating income slid 17.1% to USD 2.65 million; operating margin narrowed 1 percentage point to 31.1%.
- Gross profit edged down 15% to USD 4.76 million; gross margin tightened 0.4 percentage point to 55.8% on Filshie device tariffs.
- Management projected full-year 2026 net sales to decline 10%-13% versus 2025, citing slower-than-expected new biopharma OEM customer sales.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
"Smart money" makes massive purchases of U.S. stocks! Bank of America clients record the sixth highest weekly net purchases in history, technology stocks favored again
According to the latest client fund flow data from Bank of America, last week its clients recorded a net purchase of U.S. stocks for the second consecutive week, with the inflow reaching the highest level since mid-July. This marks the sixth largest single-week net inflow since the bank began tracking weekly data in 2008.
Academy Sports Lifts Earnings Outlook Despite Pressure on Consumer Spending
Wells Fargo Adjusts Casey's General Stores Price Target to $750 From $960, Maintains Overweight Rating
Moderna Set for 3 Near-Term INT Data Readouts, UBS Says
Crypto prices
More
